Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Mereo BioPharma Group plcNASDAQ: MREO

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes turns negative

Q1 FY2026 effect of forex changes was -$164.73K, compared with $908K a year earlier. Trailing-twelve-month effect of forex changes was $770K.

Context

  • Effect of forex changes amounted to 385.1% of revenue in FY2025.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly effect of forex changes holds near -$164.73K or moves back toward the trailing-twelve-month quarterly average of $192.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$164.73K+121.8% QoQ
Last fiscal yearDec 2025
$1.93M+926.5% YoY
LTMMar 2026
$770K+3.4% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-118.1%——
1 year+926.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
1.93M USD
Year-over-year change
+926.5%

Effect of Forex Changes vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.4% is the 3rd highest of 6, against a peer median of -100.0%.
  • Effect of forex changes amounts to 154.0% of revenue for MREO, versus a peer median of 46.1%.
MREO Competitors
Effect of Forex Changes for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMMPImmutep LimitedFY2025A$6.73M AUD+795.0%—133.4%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.62M CHF+58.7%+42.7%73.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.54M EUR-2053.4%+24.4%18.9%
MREOMereo BioPharma Group plcLTM Mar 2026$770K USD+3.4%—154.0%
SLNSilence Therapeutics plcLTM Mar 2026$54K USD——5.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 USD———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$0 USD———
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding MREO) —-100.0%+33.6%46.1%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.